[Click eStock] "MedPacto, Gene-Targeted Anticancer Drug Expected Regardless of Cancer Type"
[Asia Economy Reporter Hyungsoo Park] There is a forecast that MedPacto's anticancer drug under development, 'Bactosertib,' will become the second Larotrectinib (brand name Vitrakvi). Larotrectinib (Bayer) is the first gene-targeted anticancer drug approved for various cancer types rather than a specific cancer, and it received expedited approval from the U.S. Food and Drug Administration (FDA) in November 2018.
Hyundai Motor Securities stated on the 3rd that the clinical results of Bactosertib will be presented at the American Society of Clinical Oncology (ASCO) annual meeting held at the end of next month, and it is expected that its potential will begin to be recognized this year.
Byungguk Park, a researcher at Hyundai Motor Securities, analyzed, "It is expected that an abstract on MedPacto's desmoid tumor clinical results has been accepted at the ASCO annual meeting," adding, "Desmoid tumors are rare diseases, and there are currently no FDA-approved treatments."
He continued, "MedPacto is expected to gain recognition for its potential by presenting results not only at ASCO this year but also at subsequent international conferences such as ESMO and SITC."
Researcher Park particularly noted, "The combination potential of the TGF-beta inhibitor Bactosertib with anti-PD-1/PD-L1 immune checkpoint inhibitors such as Keytruda and Imfinzi is attracting attention."
He predicted, "Just as Larotrectinib was approved by the FDA as a gene-targeted anticancer drug regardless of cancer type, MedPacto could benchmark a similar strategy."
Hot Picks Today
"Samsung Electronics Employee with 100 Million Won Salary Receiving 600 Million Won Bonus... Estimated Tax Revealed"
- At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- "Is This Car Waterproof?" US Man in His 70s Makes Dramatic Escape After Driving Cybertruck Into Lake, Trusting Its Features
- Appearing in a Leather Jacket, Jensen Huang Hastily Eats $6 Noodles on the Street... Shop Instantly Becomes a Hotspot
Furthermore, he explained, "MedPacto, in collaboration with its parent company Theragen Etex, is analyzing the relationship between response rates and genes in ongoing clinical trials," adding, "As data accumulates and becomes big data, it may become possible to recruit patients based on specific genetic traits regardless of cancer type."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
